Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT00831597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase II trial to evaluate the efficacy and safety of combination bendamustine and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. It is hypothesized that the BR combination will produce at least a 70% overall response rate.
Study identification
- NCT ID
- NCT00831597
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2008 (Type not available)
- Primary completion
- Aug 2013 (Actual)
- Completion
- Sep 2013 (Actual)
- Last update posted
- Apr 19, 2016
2008 – 2013
United States locations
- U.S. sites
- 33
- U.S. states
- 17
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pharmatech Oncology Study Site | Beverly Hills | California | 90211 | — |
| Pharmatech Oncology Study Site | Fountain Valley | California | 92708 | — |
| Pharmatech Oncology Study Site | Oxnard | California | 93030 | — |
| Pharmatech Oncology Study Site | Washington D.C. | District of Columbia | 20037 | — |
| Pharmatech Oncology Study Site | Washington D.C. | District of Columbia | 20422 | — |
| Pharmatech Oncology Study Site | Boynton Beach | Florida | 33435 | — |
| Pharmatech Oncology Study Site | Brooksville | Florida | 34613 | — |
| Pharmatech Oncology Study Site | Gainesville | Florida | 32605 | — |
| Pharmatech Oncology Study Site | Titusville | Florida | 32796 | — |
| Pharmatech Oncology Study Site | Joliet | Illinois | 60435 | — |
| Pharmatech Oncology Study Site | Lafayette | Indiana | 47904 | — |
| Pharmatech Oncology Study Site | Muncie | Indiana | 47303 | — |
| Pharmatech Oncology Study Site | Dubuque | Iowa | 52001 | — |
| Pharmatech Oncology Study Site | Paducah | Kentucky | 42001 | — |
| Pharmatech Oncology Study Site | York Village | Maine | 03909 | — |
| Pharmatech Oncology Study Site | Jackson | Mississippi | 39202 | — |
| Pharmatech Oncology Study Site | Chesterfield | Missouri | 63017 | — |
| Pharmatech Oncology Study Site | Cherry Hill | New Jersey | 08003 | — |
| Pharmatech Oncology Study Site | Phillipsburg | New Jersey | 08865 | — |
| Pharmatech Oncology Study Site | Bay Shore | New York | 11706 | — |
| Pharmatech Oncology Study Site | East Setauket | New York | 11733 | — |
| Pharmatech Oncology Study Site | The Bronx | New York | 10467 | — |
| Pharmatech Oncology Study Site | Akron | Ohio | 44304 | — |
| Pharmatech Oncology Study Site | Columbus | Ohio | 43219 | — |
| Pharmatech Oncology Study Site | Bethlehem | Pennsylvania | 18015 | — |
| Pharmatech Oncology Study Site | Gettysburg | Pennsylvania | 17325 | — |
| Pharmatech Oncology Study Site | Hilton Head | South Carolina | 29926 | — |
| Pharmatech Oncology Study Site | Germantown | Tennessee | 38138 | — |
| Pharmatech Oncology Study Site | Austin | Texas | 78759 | — |
| Pharmatech Oncology Study Site | Corpus Christi | Texas | 78463 | — |
| Pharmatech Oncology Study Site | Fort Worth | Texas | 76104 | — |
| Pharmatech Oncology Study Site | Lubbock | Texas | 79410 | — |
| Pharmatech Oncology Study Site | Richardson | Texas | 75080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00831597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2016 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00831597 live on ClinicalTrials.gov.